# Clinical Cancer Research

## Table of Contents

### Highlights of This Issue 4731

### SPECIAL FEATURES

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Related Article Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4733</td>
<td>Prostate Cancer SubtyPINg BiomarkKers and Outcome: Is Clarity EmERGing?</td>
<td>Steven C. Smith and Scott A. Tomlins</td>
<td>p. 4904</td>
</tr>
<tr>
<td>4737</td>
<td>Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage</td>
<td>Karin C. Nitiss and John L. Nitiss</td>
<td>p. 4873</td>
</tr>
</tbody>
</table>

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4740</td>
<td>Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers</td>
<td>Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der</td>
</tr>
</tbody>
</table>

#### CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4747</td>
<td>Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors</td>
<td>Paul Haluska, Michael Menefee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso</td>
</tr>
<tr>
<td>4768</td>
<td>The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials</td>
<td>A. Schwandt, P.J. Harris, S. Hunsberger, A. Deleporte, G.L. Smith, D. Vulih, B.D. Anderson, and S.P. Ivy</td>
</tr>
</tbody>
</table>

### PERSONALIZED MEDICINE AND IMAGING

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4784</td>
<td>A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma</td>
<td>Motonobu Saito, Kouya Shiraishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kunitoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Taura, Kensuke Kumamoto, Seiichi Takenoshita, Jun Yokota, Curtis C. Harris, and Takashi Kohn</td>
</tr>
<tr>
<td>4794</td>
<td>Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform</td>
<td>Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jiong Wu, Chun-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan</td>
</tr>
<tr>
<td>4806</td>
<td>Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3'-Deoxy-3'-[18F]-Fluorothymidine Positron Emission Tomography</td>
<td>Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariarosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortosceco, Rosa Fonti, Arturo Brunetti, and Silvana Del Vecchio</td>
</tr>
</tbody>
</table>
Table of Contents

4827  Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape, Yang Ye, Razelle Kurzrock, and Donald Berry

4837  Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers
Agnieszka K. Witkiewicz, Uthra Balaji, and Erik S. Knudsen

CANCER THERAPY: PRECLINICAL

4849  PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Mohamed Rahmani, Mandy Mayo Aust, Elisa C. Benson, LaShanale Wallace, Jonathan Friedberg, and Steven Grant

4861  On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Iris Gehrke, Eric D.J. Bouchard, Sara Beiggi, Armando G. Pompilj, James B. Johnston, Spencer B. Gibson, and Versha Banerji

4873  Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
Salim Khiati, Ilaria Dalla Rosa, Carole Sourbier, Xuefei Ma, V. Ashutosh Rao, Leonard M. Neckers, Hongliang Zhang, and Yves Pommier
See related commentary, p. 4737

4882  Demethylating Drugs as Novel Analgesics for Cancer Pain
Chi T. Viet, Dongmin Dang, Yi Ye, Kentaro Oso, Ronald R. Campbell, and Brian L. Schmidt

BIOLOGY OF HUMAN TUMORS

4894  Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

4904  SPINK1 Protein Expression and Prostate Cancer Progression
Richard Flavin, Andreas Pettersson, Whitney K. Hendrickson, Michelangelo Fiorentino, Stephen Finn, Lauren Kunz, Gregory L. Judson, Rosina Lis, Dyane Bailey, Christopher Fiore, Elizabeth Nuttall, Neil E. Martin, Edward Stack, Kathryn L. Penney, Jennifer R. Rider, Jennifer Sinnott, Christopher Sweeney, Howard D. Sesso, Katja Fall, Edward Giovannucci, Philip Kantoff, Meir Stempfer, Massimo Loda, and Lorelei A. Mucci
See related commentary, p. 4733

4912  Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Anna Karlsson, Markus Ringnér, Martin Lauss, Johan Botling, Patrick Micke, Maria Planck, and Johan Staaf

4925  Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
Francesca Khani, Juan Miguel Mosquera, Kyung Park, Mirjam Blattner, Catherine O’Reilly, Theresa Y. MacDonald, Zhengming Chen, Abhishek Srivastava, Ashutosh K. Tewari, Christopher E. Barbieri, Mark A. Rubin, and Brian D. Robinson

4935  Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Michael L. Nickerson, Garrett M. Dancik, Kate M. Im, Michael G. Edwards, Sevilay Turan, Joseph Brown, Christina Ruiz-Rodriguez, Charles Owens, James C. Costello, Guangwu Guo, Shirley X. Tsang, Yingrui Li, Quan Zhou, Zhiming Cai, Lee E. Moore, M. Scott Lucia, Michael Dean, and Dan Theodorescu

4949  T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Filipe Pinto, Neila Pertega-Gomes, Márcea S. Pereira, José R. Vizcaíno, Pedro Monteiro, Rui M. Henrique, Fátima Baltazar, Raquel P. Andrade, and Rui M. Reis

See related commentary, p. 4733
Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study

Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Nima Sharifi and Richard J. Auchus

Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Response
Christopher M. Hovens, Matthew K.H. Hong, and Niall M. Corcoran

Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.